[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surfactant-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surfactant-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100403365","early-phase-1-hydroxychloroquine-in-childrens-interstitial-lung-diseases-with-genetic-causes-100403365",false,"NCT04532346","Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes","Safety and Efficacy of Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes: a Randomized Controlled Study","Inclusion Criteria:\n\n* A clinical diagnosis of chILD with age\\\u003C18 years\n* Genetically diagnosed (e.g. SFTPC, SFTPB, ABCA3, NKX2-1, CSF2RA, CSF2RB, IARS, MARS, COPA, SLC7A7, LRBA)\n* Patients have to be clinically stable with no major changes in their medication in the last 4 weeks\n* No HCQ treatment in the last 12 weeks\n* Signed and dated informed consent of the subject (if subject has the ability) and the representatives (of underaged children) must be available before start of any specific trial procedures\n\nExclusion Criteria:\n\n* Acute severe infectious exacerbations\n* Known hypersensitivity to HCQ, or other ingredients of the tablets\n* Proven retinopathy or maculopathy\n* Renal insufficiency at screening, defined as glomerular filtration rate (GFR)\\\u003C 40 mL\u002Fmin\u002F1.73 m2 in patients aged 3 to 8 weeks\\\u003C 60 mL\u002Fmin\u002F1.73 m2 in patients ≥ 8 weeks of age\n* Participation in other clinical trials during the present clinical trial","ALL","1 Month","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The aim of this proposed study is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in children's interstitial lung diseases(chILD) with genetic causes. This study is a randomized controlled clinical trial.",[27,28],"Interstitial Lung Disease","Surfactant Dysfunction","RECRUITING","2026-03-13",{"date":32,"type":33},"2026-03-16","ACTUAL",{"date":35,"type":33},"2024-09-01",{"date":37,"type":21},"2027-04",{"name":39,"class":40},"Children's Hospital of Fudan University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100422202","surfactant-for-neonatal-respiratory-distress-syndromenrds-and-neonatal-acute-respiratory-distress-syndromenards-100422202","NCT04777760","Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)","Inclusion Criteria:\n\nEligibility requirements for neonates were as follows:\n\n* The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth\n* The neonates will be diagnosed with NRDS or NARDS\n* The neonates will be at least administrated one dose of surfactant\n\nExclusion Criteria:\n\none of the following criteria will be needed\n\n* major congenital anomalies\n* chromosomal abnormalities\n* upper respiratory tract abnormalities","1 Minute","24 Hours",{"count":51,"type":21},400,"OBSERVATIONAL","In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and\u002For death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS.\n\nIn 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.",[55,56,57,28],"Respiratory Distress Syndrome","Preterm Birth","Acute Respiratory Distress Syndrome","2025-06-26",{"date":60,"type":33},"2025-07-01",{"date":62,"type":33},"2021-01-01",{"date":64,"type":21},"2026-12-31",{"name":66,"class":40},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":94,"locationsCount":41},"100439452","infants-with-severe-acute-respiratory-distress-syndrome-the-prone-trial-100439452","NCT05002478","Infants with Severe Acute Respiratory Distress Syndrome: the Prone Trial","Short-Term Effect of Prone Positioning in Infants with Severe Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Patients hospitalized at Pediatric Intensive Care Unit (PICU) or Neonatal Intensive Care Unit (NICU) of the Medical University Vienna.\n* Patients aged \\>36 weeks (corrected gestational age) and \\\u003C24 months.\n* Patient intubated and mechanically ventilated for at least 6 hours, with an expected requirement of invasive ventilatory support for at least 12 hours.\n* Clinical picture strongly suggestive for acute bronchiolitis or pneumonia (fever, fine crackles, prolonged expiration, lung hyperinflation and\u002For findings of new infiltrates consistent with acute pulmonary parenchymal disease on chest X-ray).\n* Severe pediatric acute respiratory distress syndrome (ARDS), defined by OSI ≥12.3 (wean FIO2 to maintain SpO2 ≤ 97% to calculate oxygen saturation index).\n* Written informed consent obtained from parents.\n\nExclusion Criteria:\n\n* Clinical context\n\n  * Need for O2 supplementation to maintain SpO2\\>94% in the 4 weeks preceding hospitalization in the PICU\u002FNICU\n  * Cyanotic congenital heart disease Cardiogenic pulmonary edema\n  * Severe pulmonary hypertension\n  * Untreated pneumothorax\n  * Severe neurological abnormalities\n  * Other severe congenital anomalies such as congenital diaphragmatic hernia\n  * Ongoing cardiopulmonary resuscitation or limitation of life support\n* Contradictions for prone positioning (adapted from Guerin, C., et al., Prone positioning in severe acute respiratory distress syndrome. N Engl J Med, 2013. 368(23): p. 2159-68):\n\n  * Intracranial pressure \\>30 millimeters of mercury (mmHg) in supine position or cerebral perfusion pressure \\\u003C60 mmHg\n  * Massive hemoptysis requiring an immediate surgical or interventional radiology procedure\n  * Tracheal surgery or sternotomy during the previous 15 days\n  * Serious facial trauma or facial surgery during the previous 15 days\n  * Deep venous thrombosis treated for less than 2 days\n  * Cardiac pacemaker inserted in the last 2 days\n  * Unstable spine, femur, or pelvic fractures\n  * Use of extracorporeal membrane oxygenation (ECMO) before inclusion\n  * Lung transplantation\n  * Burns on more than 20% of the body surface\n* Other non-inclusion criteria\n\n  * Indication not to attempt resuscitation\n  * Patient already recruited for other clinical studies\n  * Patients who already received surfactant in the last 4 weeks\n  * Thoracic skin lesions or wounds on the thorax, where the EIT-electrode-belt would be placed","12 Months",{"count":76,"type":21},14,[78],"NA","The main objective is to determine the short-term effect of prone positioning in infants with infection-associated severe acute respiratory distress syndrome. The investigators compare oxygenation parameters and measurements from electrical impedance tomography (EIT) and lung ultrasonography (LUS) in mechanically ventilated infants in prone position versus supine position after surfactant administration.",[81,28,82],"Acute Lung Injury\u002FAcute Respiratory Distress Syndrome (ARDS)","Infant",[57,84,85,86,87],"Electrical Impedance Tomography","Lung Ultrasonography","Prone Position","Infants","2024-11-18",{"date":90,"type":33},"2024-11-20",{"date":92,"type":33},"2022-07-30",{"date":64,"type":21},{"name":95,"class":40},"Medical University of Vienna"]